ARTICLE | Product Development
Early Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy and combos
Eearly Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy, combos
November 27, 2019 10:31 PM UTC
Updated on Dec 5, 2019 at 11:30 PM UTC
Pfizer thinks Phase I and preclinical data from its DGAT2 program suggest the target could hit NASH's three mechanistic pillars -- dysregulated metabolism, inflammation and fibrosis. The pharma is advancing a next-generation compound both alone and in combination with its ACC inhibitor.
In a Science Translational Medicine study published Wednesday, researchers from Pfizer Inc. (NYSE:PFE) showed the DGAT2 inhibitor PF-06427878 decreased hepatic steatosis and increased liver function in healthy adults and in rodent models of non-alcoholic steatohepatitis (NASH)...
BCIQ Company Profiles
BCIQ Target Profiles